Countdown to Clorox (CLX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

In its upcoming report, Clorox (CLX) is predicted by Wall Street analysts to post quarterly earnings of $2.24 per share, reflecting an increase of 23.1% compared to the same period last year. Revenues are forecasted to be $1.93 billion, representing a year-over-year increase of 1.5%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.With that in mind, let's delve into the average projections of some Clorox metrics that are commonly tracked and projected by analysts on Wall Street.The average prediction of analysts places 'Net Revenue- Health and Wellness' at $692.86 million. The estimate indicates a change of +6.3% from the prior-year quarter.Analysts forecast 'Net Revenue- International' to reach $249.98 million. The estimate suggests a change of -7.8% year over year.The consensus estimate for 'Net Revenue- Lifestyle' stands at $349.59 million. The estimate points to a change of +6.6% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Net Revenue- Household' of $626.55 million. The estimate indicates a change of +5% from the prior-year quarter.According to the collective judgment of analysts, 'Organic Revenue Growth - International' should come in at 2.4%. The estimate compares to the year-ago value of 5.0%.The consensus among analysts is that 'Income before income taxes- Health and Wellness' will reach $219.10 million. The estimate compares to the year-ago value of $202.00 million.Analysts predict that the 'Income before income taxes- International' will reach $21.21 million. The estimate compares to the year-ago value of $18.00 million.The combined assessment of analysts suggests that 'Income before income taxes- Lifestyle' will likely reach $71.73 million. Compared to the present estimate, the company reported $61.00 million in the same quarter last year.It is projected by analysts that the 'Income before income taxes- Household' will reach $102.89 million. The estimate compares to the year-ago value of $98.00 million. View all Key Company Metrics for Clorox here>>> Clorox shares have witnessed a change of +2.8% in the past month, in contrast to the Zacks S&P 500 composite's +3.4% move. With a Zacks Rank #5 (Strong Sell), CLX is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Clorox Company (CLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks